# THESIS: NEAR Intents earns real fees, but its moat is not yet proven *Data snapshot Nov 14, 2026. Verdict: **Weak moat evidence** (1 of 3 pre-registered tests passed). Dashboard: (source: `site/index.html`). Rules: [METHODS.md](METHODS.md). Machine-readable results: [results/results.json](results/results.json).* ## Claim Other theses in this track establish that NEAR Intents generates real fee revenue. That alone does not justify a multiple. Revenue deserves a high multiple only if it is **defensible**, so this thesis tests defensibility directly, three ways, each against a synthetic control built from competitors: | Test | Question | Result | Verdict | |---|---|---|---| | T1 Pricing power | When NEAR started taking a cut on Feb 23, 2026, did volume leave? | +16% vs control over 8 weeks | PASS | | T2 Trust shock | After the Oct 1, 2026 exploit, did volume come back? | -21% vs control in weeks 4–5 (p = 0.05) | FAIL | | T3 Price premium | Does Intents charge more than rivals and keep share? | 14.9 vs 17.7 bps median; dearer in 8% of weeks | FAIL | **The claim:** NEAR Intents has shown it can tax its own flow without losing it, but it has not shown a moat. It wins on price, and its flow may be sensitive to trust. The bull case for NEAR rests on fee revenue that a cheaper or safer competitor could, in principle, take. - **The fee switch did not cost volume.** NEAR raised its share of fees and volume kept pace with competitors. Taking a cut has not driven integrators away, so far. - **Intents is the cheaper venue, not the premium one.** Its users pay less than on native cross-chain rivals. That is a growth strategy, not evidence of a moat: a cheaper rival could compete the same way. - **Trust is the open risk.** Volume trailed its control by weeks 4–5 after the exploit. The signal passes the pre-registered test but is fragile under robustness checks; it is the number to watch. ## Evidence for - **The fee switch cost nothing measurable.** NEAR's share of fees rose from 7.8% to 13.8%, while users' fee rate went from 18.0 to 17.6 bps. Over the next 8 weeks Intents ran +16% against its synthetic control. Robustness: dropping any one control gives +16% to +31%; a 13-week pre-window gives +25%; adding contaminated controls gives +18%. - **Share against Chainflip is holding.** Over May 16, 2026 to Nov 13, 2026, Intents' share against Chainflip moved from 75% to 82%; the weekly trend is -0.14% (90% CI -0.52% to +0.30%). That broader comparison points to share slipping against the larger rival, so “holding” applies to Chainflip only. - **No immediate flight after the exploit.** The gap to control in weeks 0–1 was -1%. ## Evidence against - **No price premium.** Intents' median fee rate was 14.9 bps against 17.7 bps for THORChain, Chainflip and Maya combined; Intents was dearer in only 8% of 26 weeks. A venue that is cheapest is winning on price, which a rival can match. - **Post-exploit underperformance.** By weeks 4–5 Intents trailed its control by -21%. Against 63 placebo windows p = 0.05; against the 34 windows dated 2026, p = 0.09. - **Growth lead has gone.** In 2025 Intents outgrew its competitors in every placebo window (median +430% over 8 weeks). The real post-switch figure, +16%, sits below all 29 of them. The lead had already shrunk by January 2026, before the switch, so this is a maturing business, not a switch effect, but it removes "hypergrowth" as an argument. ## How sure is this - **T1** rests on a loose pre-period fit (RMSPE 0.57 log points): no mix of mature competitors tracks Intents' 2025 growth well. The direction (no loss) is consistent across every robustness check; the size is not precise. - **T2** has a close fit (RMSPE 0.13) but is fragile: dropping one control moves it between -63% and +12%; difference-in-differences gives -49%; adding contaminated controls gives +27%. Intents ranks 5 of 5 in the placebo-in-space test. Week by week: wk 0: -25%, wk 1: +29%, wk 2: -14%, wk 3: -3%, wk 4: -24%, wk 5: -18%. - **T3** compares DefiLlama-reported fees, whose definitions differ by venue. Against THORChain and Chainflip over the 21 weeks both report, the share trend is -1.98% a week, steeper than the headline. - The placebo-in-time test was pre-registered as conservative. It is not: most placebo windows fall in 2025's hypergrowth, which shifts the distribution up. This is disclosed in METHODS.md section 8, and the 2026-only p-value is reported beside the pre-registered one. ## Checked on-chain DefiLlama is an aggregator, so the build also reads 3,346 NEAR blocks directly (keyless, from neardata.xyz) and counts what `intents.near` executed in each. - **The aggregator loosely tracks the chain.** Weekly on-chain executed intents and DefiLlama volume correlate at 0.67 in levels and 0.42 in week-to-week changes, over 32 weeks. - **The fee switch, on-chain.** Executed intents in the 8 weeks after Feb 23 were -3% against the 8 weeks before; DefiLlama volume was -17%. - **The exploit, on-chain.** On-chain activity moved the same way, far more strongly: executed intents in weeks 4–5 after Oct 1 were +88% against the 8 weeks before; DefiLlama volume was +7%. This raw before/after has no competitor control, so it does not contradict T2: both measures can rise while Intents loses ground to rivals. - **The pause, on-chain.** In blocks sampled every 30 minutes, the longest run with no `intents.near` activity was 5 samples (about 2.5 hours), 2026-10-01 08:48 UTC to 2026-10-01 11:00 UTC. Before Oct 1, 28% of sampled blocks already had none, so a run this long would appear somewhere in 144 samples 15% of the time by chance. The sample is consistent with a pause of a few hours but cannot pin one down. - **Solvers.** Over the last 8 weeks, 13 repeat counterparties appear in `token_diff` swap events. The top one carries 36% and the top 3 carry 60% (HHI 0.18): moderately concentrated. ## The long-term case for NEAR Holders are diluted by issuance, and Intents revenue is what can offset it. From block headers, NEAR's supply grew 31.7M NEAR (2.48%) in the last year: $138.0M at the 30-day average price of $4.35. Annualised Intents revenue is $21.8M, so revenue equals **16%** of issuance value. Revenue = volume × fee rate × NEAR's cut. The moat tests say which lever is safe: | Lever | Trailing 12 weeks | Evidence | |---|---|---| | NEAR's cut | 28% | T1: raising it did not cost volume. Covering issuance would need 175%, so this lever cannot cover issuance on its own, even at 100% capture. | | Fee rate | 15.5 bps | T3: already cheaper than rivals, with no premium to spend. | | Volume | $50.9B a year | T2: exposed to trust. At today's cut and fee rate it must grow 6.3× to cover issuance. | **Long-term reading.** The thesis for NEAR is a volume-growth thesis, not a pricing-power thesis, and that volume depends on trust. Watch incident recovery and solver depth more than fee rates. ## What would change my mind Checkable by re-running `python3 -m zeat refresh && python3 -m zeat build` after the date shown. 1. **Trust (by 2027-01-15).** If, with weeks 6–15 after the exploit available, Intents' gap to its control is no worse than −10%, the trust concern is withdrawn and T2 should be read as a pass. 2. **Premium (by 2027-02-15).** If Intents' fee rate is above the competitor rate in at least 75% of the weeks from 2026-11-12 onward while its share holds, it has pricing power and T3 flips. 3. **Capture (by 2027-02-15).** If NEAR's share of Intents fees falls back below 10% for 8 straight weeks, the "fee switch cost nothing" result no longer holds, because the cut was given back. 4. **Competition.** If a rival venue matches Intents' fee rate and Intents' share against it falls for 8 straight weeks, the "wins on price" reading is confirmed as a weakness, not a strategy. ## Scope Not financial advice. This thesis tests defensibility of NEAR Intents' fee revenue only. It does not value the NEAR token, and it does not measure solver concentration, which public data could not support (see METHODS.md section 7).